Studies in syngeneic mouse models revealed that engagement of activating FcγRs by anti-PD-L1 antibodies augments their anti-tumor activity and that this effect was partially mediated by depletion of PD-L1-expressing MDSC (13). This evidence concerns the gene CD274 and neoplasm.